Safety of nanoparticle albumin‑bound paclitaxel administered to breast cancer patients with clinical contraindications to paclitaxel or docetaxel: Four case reports

  • Authors:
    • Kosei Kimura
    • Satoru Tanaka
    • Mitsuhiko Iwamoto
    • Hiroya Fujioka
    • Yuko Takahashi
    • Nayuko Sato
    • Risa Terasawa
    • Tomo Tominaga
    • Ayana Ikari
    • Kazuhisa Uchiyama
  • View Affiliations

  • Published online on: July 17, 2013     https://doi.org/10.3892/ol.2013.1471
  • Pages: 881-884
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Taxanes, including paclitaxel (PTX) and docetaxel (DOC), are poorly soluble in water due to their hydrophobic properties and thus, require solvents. However, use of these solvents has been associated with toxic responses, including a hypersensitivity reaction (HSR). Nanoparticle albumin‑bound paclitaxel (nab‑PTX) is a novel formulation of PTX, which allows reconstitution of the agent with a saline solution instead of solvents and administration without premedication for HSRs. The current study reports the safe administration of nab‑PTX to four breast cancer patients considered clinically to have contraindications to PTX or DOC. Two of the patients had previously experienced HSRs to PTX or DOC and the other two patients had contraindications to steroids as a premedication for HSRs, since one patient suffered from diabetes and the other was a carrier of the hepatitis B virus. All 4 patients were safely administered nab‑PTX. In conclusion, administration of nab‑PTX appears to be effective for patients that have previously experienced HSRs to other taxanes or in those with contraindications to steroids.
View Figures
View References

Related Articles

Journal Cover

October 2013
Volume 6 Issue 4

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Kimura K, Tanaka S, Iwamoto M, Fujioka H, Takahashi Y, Sato N, Terasawa R, Tominaga T, Ikari A, Uchiyama K, Uchiyama K, et al: Safety of nanoparticle albumin‑bound paclitaxel administered to breast cancer patients with clinical contraindications to paclitaxel or docetaxel: Four case reports. Oncol Lett 6: 881-884, 2013
APA
Kimura, K., Tanaka, S., Iwamoto, M., Fujioka, H., Takahashi, Y., Sato, N. ... Uchiyama, K. (2013). Safety of nanoparticle albumin‑bound paclitaxel administered to breast cancer patients with clinical contraindications to paclitaxel or docetaxel: Four case reports. Oncology Letters, 6, 881-884. https://doi.org/10.3892/ol.2013.1471
MLA
Kimura, K., Tanaka, S., Iwamoto, M., Fujioka, H., Takahashi, Y., Sato, N., Terasawa, R., Tominaga, T., Ikari, A., Uchiyama, K."Safety of nanoparticle albumin‑bound paclitaxel administered to breast cancer patients with clinical contraindications to paclitaxel or docetaxel: Four case reports". Oncology Letters 6.4 (2013): 881-884.
Chicago
Kimura, K., Tanaka, S., Iwamoto, M., Fujioka, H., Takahashi, Y., Sato, N., Terasawa, R., Tominaga, T., Ikari, A., Uchiyama, K."Safety of nanoparticle albumin‑bound paclitaxel administered to breast cancer patients with clinical contraindications to paclitaxel or docetaxel: Four case reports". Oncology Letters 6, no. 4 (2013): 881-884. https://doi.org/10.3892/ol.2013.1471